scispace - formally typeset
Search or ask a question
Author

Eric P. Goosby

Bio: Eric P. Goosby is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Medicine & Welfare. The author has an hindex of 4, co-authored 4 publications receiving 5158 citations.

Papers
More filters
Journal Article•DOI•
TL;DR: These Guidelines were developed by the Panel* on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services and the Henry J. Kaiser Family Foundation.
Abstract: SUMMARY The availability of an increasing number of antiretroviral agents and the rapid evolution of new information has introduced extraordinary complexity into the treatment of HIV-infected persons. In 1996, the Department of Health and Human Services and the Henry J. Kaiser Family Foundation convened the Panel on Clinical Practices for the Treatment of HIV to develop guidelines for the clinical management of HIV-infected adults and adolescents. This report recommends that care should be supervised by an expert, and makes recommendations for laboratory monitoring including plasma HIV RNA, CD4 cell counts and HIV drug resistance testing. The report also provides guidelines for antiretroviral therapy, including when to start treatment, what drugs to initiate, when to change therapy, and therapeutic options when changing therapy. Special considerations are provided for adolescents and pregnant women. As with treatment of other chronic conditions, therapeutic decisions require a mutual understanding between the patient and the health care provider regarding the benefits and risks of treatment. Antiretroviral regimens are complex, have major side effects, pose difficulty with adherence, and carry serious potential consequences from the development of viral resistance due to non-adherence to the drug regimen or suboptimal levels of antiretroviral agents. Patient education and involvement in therapeutic

4,321 citations

Journal Article•DOI•
Henry Masur1, Jonathan E. Kaplan1, King K. Holmes1, Beverly Alston1, Miriam J. Alter1, Neil M. Ampel1, Jean Anderson1, A. Cornelius Baker1, David A Barr1, John G. Bartlett1, John E. Bennett1, Constance A. Benson1, William A. Bower1, Samuel A. Bozzette1, John T. Brooks1, Victoria A. Cargill1, Kenneth G. Castro1, Richard E. Chaisson1, David A. Cooper1, Clyde S. Crumpacker1, Judith S. Currier1, Kevin M. DeCock1, Lawrence Deyton1, Scott F. Dowell1, W. Lawrence Drew1, William Duncan1, Mark S. Dworkin1, Clare A. Dykewicz1, Robert W Eisinger1, Tedd Ellerbrock1, Wafaa El-Sadr1, Judith Feinberg1, Kenneth A. Freedberg1, Keiji Fukuda1, Hansjakob Furrer1, Jose M. Gatell1, John W. Gnann1, Mark J. Goldberger1, Sue Goldie1, Eric P. Goosby1, Fred M. Gordin1, Peter A. Gross1, Rana Hajjeh1, Richard Hafner1, Diane Havlir1, S D Holmberg1, David R. Holtgrave1, Thomas M. Hooton1, Douglas A. Jabs1, Mark A. Jacobson1, Harold Jaffe1, Edward N. Janoff1, Jeffrey M. Jones1, Dennis D. Juranek1, Mari M. Kitahata1, Joseph A. Kovacs1, Catherine Leport1, Myron J. Levin1, Juan C. Lopez1, Jens D Lundgren1, Michael Marco1, Eric Mast1, Douglas L. Mayers1, Lynne M. Mofenson1, Julio Montaner1, Richard A. Moore1, Thomas Navin1, James D. Neaton1, Charles Nelson1, Joseph F. O'Neill1, Joel Palefsky1, Alice Pau1, Phil Pellett1, John P. Phair1, Steve Piscitelli1, Michael A. Polis1, Thomas C. Quinn1, William C. Reeves1, Peter Reiss1, David Rimland1, Anne Schuchat1, Cynthia L. Sears1, Leonard B. Seeff1, Kent A. Sepkowitz1, Kenneth E. Sherman1, Thomas G. Slama1, Elaine M. Sloand1, Stephen A. Spector1, John A. Stewart1, David L. Thomas1, Timothy M. Uyeki1, Russell Van Dyke1, M. Elsa Villarino1, Anna Wald1, D. Heather Watts1, L. Joseph Wheat1, Paige L. Williams1, Thomas C. Wright1 •
TL;DR: This fourth edition of the guidelines for preventing opportunistic infections (OIs) among persons infected with human immunodeficiency virus (HIV) is intended for clinicians and other health-care providers who care for HIV-infected persons.
Abstract: In 1995, the U.S. Public Health Service (USPHS) and the Infectious Diseases Society of America (IDSA) developed guidelines for preventing opportunistic infections (OIs) among persons infected with human immunodeficiency virus (HIV); these guidelines were updated in 1997 and 1999. This fourth edition of the guidelines, made available on the Internet in 2001, is intended for clinicians and other health-care providers who care for HIV-infected persons. The goal of these guidelines is to provide evidence-based guidelines for preventing OIs among HIV-infected adults and adolescents, including pregnant women, and HIV-exposed or infected children. Nineteen OIs, or groups of OIs, are addressed, and recommendations are included for preventing exposure to opportunistic pathogens, preventing first episodes of disease by chemoprophylaxis or vaccination (primary prophylaxis), and preventing disease recurrence (secondary prophylaxis). Major changes since the last edition of the guidelines include 1) updated recommendations for discontinuing primary and secondary OI prophylaxis among persons whose CD4+ T lymphocyte counts have increased in response to antiretroviral therapy; 2) emphasis on screening all HIV-infected persons for infection with hepatitis C virus; 3) new information regarding transmission of human herpesvirus 8 infection; 4) new information regarding drug interactions, chiefly related to rifamycins and antiretroviral drugs; and 5) revised recommendations for immunizing HIV-infected adults and adolescents and HIV-exposed or infected children.

559 citations

Journal Article•
TL;DR: In August 1999, agencies of the U.S. Public Health Service (USPHS), in collaboration with the Infectious Diseases Society of American (IDSA), published 1999 Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus (HIV).
Abstract: In August 1999, agencies of the U.S. Public Health Service (USPHS), in collaboration with the Infectious Diseases Society of American (IDSA), published 1999 Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus (HIV) (1). These guidelines are an update of those prepared in 1995 and 1997 and published in several venues, including Annals of Internal Medicine (2, 3). They are intended primarily for health care providers who care for HIV-infected persons and are reproduced here in an effort to reach and as a service to all internists who care for HIV-infected patients. Single copies of the 1999 USPHS/IDSA guidelines can be obtained from the AIDS Treatment Information Service (ATIS) by calling 800-448-0440, 301-217-0023 (international), or 800-243-7012 (TYY) or by downloading the document from the ATIS Web site at www.hivatis.org. References 1. USPHS/IDSA Prevention of Opportunistic Infections Working Group. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep. 1999; 48(RR-10):1-66. 2. USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. Ann Intern Med. 1996; 124:348-68. 3. USPHS/IDSA Prevention of Opportunistic Infections Working Group. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Ann Intern Med. 1997; 127:922-46. Members of the USPHS/IDSA Prevention of Opportunistic Infections Working Group The working group was chaired by Henry Masur, MD, National Institutes of Health, Bethesda, MD; Jonathan E. Kaplan, MD, Centers for Disease Control and Prevention, Atlanta; and King K. Holmes, MD, PhD, University of Washington, Seattle. Members of the group included Beverly L. Alston, MD (National Institutes of Health, Bethesda, MD); Neil Ampel, MD (University of Arizona, Tucson); Jean R. Anderson, MD (Johns Hopkins University, Baltimore); A. Cornelius Baker (National Association of People with AIDS, Washington, DC); David Barr (Forum for Collaborative HIV Research, Washington, DC); John G. Bartlett, MD (Johns Hopkins University, Baltimore); John E. Bennett, MD (National Institutes of Health, Bethesda, MD); Constance A. Benson, MD (University of Colorado, Denver); Samual A. Bozzette, MD (University of California, San Diego); Richard E. Chaisson, MD (Johns Hopkins University, Baltimore); Clyde S. Crumpacker, MD (Harvard Medical Center, Boston); Judith S. Currier, MD, MSc (University of California-Los Angeles Medical Center, Los Angeles); Lawrence Deyton, MD, MSPH (U.S. Department of Veterans Affairs, Washington, DC); W. Lawrence Drew, MD, PhD (Mt. Zion Medical Center, University of California-San Francisco, San Francisco); William R. Duncan, PhD (National Institutes of Health, Bethesda, MD); Robert W. Eisinger, PhD (National Institutes of Health, Bethesda, MD); Wafaa El-Sadr, MD, MPH, MPA (Harlem Hospital, New York); Judith Feinberg, MD (Holmes Hospital, Cincinnati); Kenneth A. Freedberg, MD, MSc (Boston University School of Medicine, Boston); Hansjakob Furrer, MD (University Hospital, Berne, Switzerland); John W. Gnann Jr., MD (University of Alabama, Birmingham); Mark J. Goldberger, MD, MPH (U.S. Food and Drug Administration, Rockville, MD); Sue Goldie, MD, PhD (Harvard School of Public Health, Boston); Eric P. Goosby, MD (U.S. Department of Health and Human Services, Washington, DC); Peter A. Gross, MD (Hackensack Medical Center, Hackensack, NJ); Richard Hafner, MD (National Institutes of Health, Bethesda, MD); Diane Havlir, MD (University of California, San Diego); Thomas M. Hooton, MD (Harborview Medical Center, Seattle); Douglas A. Jabs, MD (Johns Hopkins University, Baltimore); Mark A. Jacobson, MD (University of California, San Francisco); Edward Janoff, MD (Veterans Administration Medical Center, Minneapolis); Mari Kitahata, MD, PhD (University of Washington, Seattle); Joseph V. Kovacs, MD (National Institutes of Health, Bethesda, MD); Catherine Leport, MD (Hospital Bichat-Claude Bernard, Paris); Myron J. Levin, MD (University of Colorado Health Science Center, Denver); Juan C. Lopez, MD (Hospital Universatario Gregorio Maranon, Madrid); Michael Marco (Treatment Action Group, New York); Douglas L. Mayers, MD (Henry Ford Hospital, Detroit); David A. Melnick, MD (Kaiser Permanente, Springfield, VA); Lynne M. Mofenson, MD (National Institutes of Health, Bethesda, MD); Julio S.G. Montaner, MD (St. Paul's Hospital, Vancouver); Richard Moore, MD (Johns Hopkins University, Baltimore); James Neaton, PhD (University of Minnesota, Minneapolis); Charles Nelson (National Association of People with AIDS, Washington, DC); Joseph F. O'Neill, MD, MS, MPH (Health Resources and Services Administration, Rockville, MD); Joel Palefsky, MD (University of California, San Francisco); Alice Pau, PharmD (National Institutes of Health, Bethesda, MD); John P. Phair, MD (Northwestern University, Chicago); Stephen Piscitelli, PharmD (National Institutes of Health, Bethesda, MD); Michael A. Polis, MD, MPH (National Institutes of Health, Bethesda, MD); Thomas C. Quinn, MD (Johns Hopkins Hospital, Baltimore); Peter Reiss, MD, PhD (University of Amsterdam, Amsterdam); David Rimland, MD (Veterans Administration Medical Center, Atlanta); Cynthia L. Sears, MD (Johns Hopkins University, Baltimore); Leonard Seeff, MD (National Institutes of Health, Bethesda, MD); Kent A. Sepkowitz, MD (Memorial Sloan-Kettering Cancer Center, New York); Thomas G. Slama, MD (National Foundation for Infectious Diseases, Indianapolis); Elaine M. Sloand, MD (National Institutes of Health, Bethesda, MD); Stephen A. Spector, MD (University of California, La Jolla); David L. Thomas, MD, MPH (Johns Hopkins University, Baltimore); Russell B. Van Dyke, MD (Tulane School of Medicine, New Orleans, LA); D. Heather Watts, MD (National Institutes of Health, Bethesda, MD); L. Joseph Wheat, MD (Indiana University School of Medicine, Indianapolis); Scott M. Whitcup, MD (National Institutes of Health, Bethesda, MD); Paige Williams, PhD (Harvard School of Public Health, Boston); Thomas C. Wright Jr., MD (Columbia University College of Physicians and Surgeons, New York). Participants from the Centers for Disease Control and Prevention, Atlanta, included Kenneth G. Castro, MD, Kevin M. DeCock, MD, DTM&H, Scott F. Dowell, MD, MPH, Mark S. Dworkin, MD, MPHTM, Clare Dykewicz, MD, MPH, Tedd Ellerbrock, MD, Rana Hajjeh, MD, Scott Holmberg, MD, MPH, David R. Holtgrave, PhD, Harold W. Jaffe, MD, Jeffrey L. Jones, MD, Dennis D. Juranek, DVM, MSc, Eric Mast, MD, MPH, Thomas Navin, MD, Phil E. Pellett, PhD, William C. Reeves, MD, MPH, John A. Stewart, MD, and M. Elsa Villarino, MD, MPH. This report was prepared by Jonathan E. Kaplan, MD (Division of AIDS, STD, and TB Laboratory Research, National Center for Infectious Diseases and Division of HIV/AIDS PreventionSurveillance and Epidemiology, National Center for HIV, STD, and TB Prevention) in collaboration with Henry Masur, MD (National Institutes of Health) and King K. Holmes, MD, PhD (University of Washington). PREFACE In 1995, the U.S. Public Health Service (USPHS) and the Infectious Diseases Society of America (IDSA) developed guidelines for preventing opportunistic infections (OIs) in persons infected with human immunodeficiency virus (HIV) (1-3). These guidelines, written for health-care providers and patients, were revised in 1997 and published in MMWR (4), Clinical Infectious Diseases (5), Annals of Internal Medicine (6), American Family Physician (7), and Pediatrics (8); an accompanying editorial appeared in JAMA (9). Response to these guidelines (e.g., the many requests for reprints and observations from health-care providers) suggests they have served as a valuable reference for HIV care providers. Because the 1995 and 1997 guidelines included ratings indicating the strength of each recommendation and the quality of supporting evidence, readers were able to assess the relative importance of each recommendation. Since AIDS was first recognized nearly 20 years ago, remarkable progress has been made in improving the quality and duration of life of HIV-infected persons. During the first decade of the epidemic, this improvement occurred because of better recognition of opportunistic disease processes, better therapy for acute and chronic complications, and the introduction of chemoprophylaxis against Pneumocystis carinii pneumonia (PCP), toxoplasmosis, Mycobacterium avium complex (MAC) disease, and bacterial infections. Trimethoprim-sulfamethoxazole (TMP-SMZ) was shown to reduce the incidence not only of PCP but also of toxoplasmosis and bacterial infections. The second decade of the epidemic has witnessed extraordinary progress in developing highly active antiretroviral therapies (HAARTs) as well as continuing progress in preventing and treating individual OIs. HAART has reduced the incidence of OIs and extended life substantially (10). HAART is the most effective approach to preventing OIs and should be considered for all HIV-infected persons who qualify for such therapy. However, some patients are not ready or able to take HAART, and others have tried HAART regimens, but therapy has failed. Such patients will benefit from prophylaxis against OIs. In addition, prophylaxis against specific OIs continues to provide survival benefits even among persons who are receiving HAART (11). Because important new data concerning the prevention of opportunistic diseases have emerged since 1997, the USPHS and the IDSA reconvened the Prevention of Opportunistic Infections Working Group on March 4 and 5, 1999, to determine which recommendations warranted revision. Participants included representatives from federal agencies, universities, and professional societies, as well as commun

164 citations

01 Jan 2000
TL;DR: These recommendations update the 1994 guidelines developed by the Public Health Service for the use of zidovudine (ZDV) to reduce the risk for perinatal human immunodeficiency virus type 1 (HIV-1) transmission.
Abstract: SUMMARY These recommendations update the 1994 guidelines developed by the Public Health Service for the use of zidovudine (ZDV) to reduce the risk for perinatal human immunodeficiency virus type 1 (HIV-1) transmission. This report provides health care providers with information for discussion with HIV-1 infected pregnant women to enable such women to make an informed decision regarding the use of antiretroviral drugs during pregnancy. Various circumstances that commonly occur in clinical practice are presented as scenarios and the factors influencing treatment considerations are highlighted in this report. It is recognized that strategies to prevent perinatal transmission and concepts related to management of HIV disease in pregnant women are rapidly evolving. The Perinatal HIV Guidelines Working Group will review new data on an ongoing basis and provide

124 citations

Journal Article•DOI•
TL;DR: In this paper , the authors estimated that US life expectancy at birth dropped by 3.08 years due to the million COVID-19 deaths between February 2020 and May 2022, and the combined impact on national income growth and the added value of lives lost was in the order of US$3.57 trillion.
Abstract: Abstract Between February 2020 and May 2022, one million Americans have died of COVID-19. To determine the contribution of those deaths to all-cause mortality in terms of life expectancy reductions and the resulting economic welfare losses, we calculated their combined impact on national income growth and the added value of lives lost. We estimated that US life expectancy at birth dropped by 3.08 years due to the million COVID-19 deaths. Economic welfare losses estimated in terms of national income growth supplemented by the value of lives lost , was in the order of US$3.57 trillion. US$2.20 trillion of these losses were in in the non-Hispanic White population (56.50%), US$698.24 billion (19.54%) in the Hispanic population, and US$579.93 billion (16.23%) in the non-Hispanic Black population. The scale of life expectancy and welfare losses underscores the pressing need to invest in health in the US to prevent further economic shocks from future pandemic threats.

3 citations


Cited by
More filters
Journal Article•DOI•
TL;DR: These Guidelines were developed by the Panel* on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services and the Henry J. Kaiser Family Foundation.
Abstract: SUMMARY The availability of an increasing number of antiretroviral agents and the rapid evolution of new information has introduced extraordinary complexity into the treatment of HIV-infected persons. In 1996, the Department of Health and Human Services and the Henry J. Kaiser Family Foundation convened the Panel on Clinical Practices for the Treatment of HIV to develop guidelines for the clinical management of HIV-infected adults and adolescents. This report recommends that care should be supervised by an expert, and makes recommendations for laboratory monitoring including plasma HIV RNA, CD4 cell counts and HIV drug resistance testing. The report also provides guidelines for antiretroviral therapy, including when to start treatment, what drugs to initiate, when to change therapy, and therapeutic options when changing therapy. Special considerations are provided for adolescents and pregnant women. As with treatment of other chronic conditions, therapeutic decisions require a mutual understanding between the patient and the health care provider regarding the benefits and risks of treatment. Antiretroviral regimens are complex, have major side effects, pose difficulty with adherence, and carry serious potential consequences from the development of viral resistance due to non-adherence to the drug regimen or suboptimal levels of antiretroviral agents. Patient education and involvement in therapeutic

4,321 citations

Journal Article•DOI•
TL;DR: This Clinical Practice Guideline presents updated recommendations for the optimal management of HBV infection, and future treatment strategies to achieve 'cure' of disease and new biomarkers are discussed.

3,016 citations

Journal Article•
TL;DR: The objectives of these recommendations are to increase HIV screening of patients, including pregnant women, in health-care settings; foster earlier detection of HIV infection; identify and counsel persons with unrecognized HIV infection and link them to clinical and prevention services; and further reduce perinatal transmission of HIV in the United States.
Abstract: These recommendations for human immunodeficiency virus (HIV) testing are intended for all health-care providers in the public and private sectors, including those working in hospital emergency departments, urgent care clinics, inpatient services, substance abuse treatment clinics, public health clinics, community clinics, correctional health-care facilities, and primary care settings. The recommendations address HIV testing in health-care settings only. They do not modify existing guidelines concerning HIV counseling, testing, and referral for persons at high risk for HIV who seek or receive HIV testing in nonclinical settings (e.g., community-based organizations, outreach settings, or mobile vans). The objectives of these recommendations are to increase HIV screening of patients, including pregnant women, in health-care settings; foster earlier detection of HIV infection; identify and counsel persons with unrecognized HIV infection and link them to clinical and prevention services; and further reduce perinatal transmission of HIV in the United States. These revised recommendations update previous recommendations for HIV testing in health-care settings and for screening of pregnant women (CDC. Recommendations for HIV testing services for inpatients and outpatients in acute-care hospital settings. MMWR 1993;42[No. RR-2]:1-10; CDC. Revised guidelines for HIV counseling, testing, and referral. MMWR 2001;50[No. RR-19]:1-62; and CDC. Revised recommendations for HIV screening of pregnant women. MMWR 2001;50[No. RR-19]:63-85). Major revisions from previously published guidelines are as follows: For patients in all health-care settings HIV screening is recommended for patients in all health-care settings after the patient is notified that testing will be performed unless the patient declines (opt-out screening). Persons at high risk for HIV infection should be screened for HIV at least annually. Separate written consent for HIV testing should not be required; general consent for medical care should be considered sufficient to encompass consent for HIV testing. Prevention counseling should not be required with HIV diagnostic testing or as part of HIV screening programs in health-care settings. For pregnant women HIV screening should be included in the routine panel of prenatal screening tests for all pregnant women. HIV screening is recommended after the patient is notified that testing will be performed unless the patient declines (opt-out screening). Separate written consent for HIV testing should not be required; general consent for medical care should be considered sufficient to encompass consent for HIV testing. Repeat screening in the third trimester is recommended in certain jurisdictions with elevated rates of HIV infection among pregnant women.

2,958 citations

Journal Article•DOI•
TL;DR: The ability of hospital ventilation systems to filter Aspergillus and other fungi following a building implosion and the impact of bedside design and furnishing on nosocomial infections are investigated.

2,632 citations

Journal Article•DOI•
TL;DR: Nevirapine lowered the risk of HIV-1 transmission during the first 14-16 weeks of life by nearly 50% in a breastfeeding population, suggesting this simple and inexpensive regimen could decrease mother-to-child HIV- 1 transmission in less-developed countries.

1,766 citations